Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1997 Apr;62(4):391–394. doi: 10.1136/jnnp.62.4.391

Long term follow up of multifocal motor neuropathy with conduction block under treatment.

J P Azulay 1, P Rihet 1, J Pouget 1, F Cador 1, O Blin 1, J Boucraut 1, G Serratrice 1
PMCID: PMC1074100  PMID: 9120457

Abstract

Eighteen patients (15 men, three women; age range 30 to 71 years, mean 45.8 years) with multifocal motor neuropathy treated with high dose intravenous immunoglobulin (IVIg) were evaluated for nine to 48 months (mean follow up 25.3 months). The median time between onset of multifocal motor neuropathy and treatment was 5.8 years. The dose of IVIg was 0.4 g/day for three to five days. The interval between each treatment was determined for each patient by the evaluation of the effect of the first course. Muscle strength was evaluated by a computerised analyser. Clinical improvement was seen in 12 patients treated with IVIg (67%). Isometric strength increased from 32% to 97% (mean 54.5%) of the initial value. Functional scales corroborated these findings. No clear predictive factors of response to IVIg was found except the presence of high titres of IgM anti-GM1 antibodies. Often, patients needed repeated courses of IVIg to maintain the improvement. In two patients, IVIg infusions were stopped without signs of relapse after one year. Four patients were initially treated with prednisone (1 mg/kg/day), without any clear improvement. Five patients with no response to IVIg or who were IVIg dependent were treated with cyclophosphamide, but only one showed improvement. These results show the long term benefits and safety of IVIg in multifocal motor neuropathy but also the transient effect of this expensive treatment in most patients.

Full text

PDF
391

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Azulay J. P., Blin O., Pouget J., Boucraut J., Billé-Turc F., Carles G., Serratrice G. Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994 Mar;44(3 Pt 1):429–432. doi: 10.1212/wnl.44.3_part_1.429. [DOI] [PubMed] [Google Scholar]
  2. Bouche P., Moulonguet A., Younes-Chennoufi A. B., Adams D., Baumann N., Meininger V., Léger J. M., Said G. Multifocal motor neuropathy with conduction block: a study of 24 patients. J Neurol Neurosurg Psychiatry. 1995 Jul;59(1):38–44. doi: 10.1136/jnnp.59.1.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Chad D. A., Hammer K., Sargent J. Slow resolution of multifocal weakness and fasciculation: a reversible motor neuron syndrome. Neurology. 1986 Sep;36(9):1260–1263. doi: 10.1212/wnl.36.9.1260. [DOI] [PubMed] [Google Scholar]
  4. Charles N., Benoit P., Vial C., Bierme T., Moreau T., Bady B. Intravenous immunoglobulin treatment in multifocal motor neuropathy. Lancet. 1992 Jul 18;340(8812):182–182. doi: 10.1016/0140-6736(92)93267-q. [DOI] [PubMed] [Google Scholar]
  5. Dalakas M. C., Stein D. P., Otero C., Sekul E., Cupler E. J., McCrosky S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol. 1994 Sep;51(9):861–864. doi: 10.1001/archneur.1994.00540210031010. [DOI] [PubMed] [Google Scholar]
  6. Donaghy M., Mills K. R., Boniface S. J., Simmons J., Wright I., Gregson N., Jacobs J. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobulin. J Neurol Neurosurg Psychiatry. 1994 Jul;57(7):778–783. doi: 10.1136/jnnp.57.7.778. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Elliott J. L., Pestronk A. Progression of multifocal motor neuropathy during apparently successful treatment with human immunoglobulin. Neurology. 1994 May;44(5):967–968. doi: 10.1212/wnl.44.5.967. [DOI] [PubMed] [Google Scholar]
  8. Feldman E. L., Bromberg M. B., Albers J. W., Pestronk A. Immunosuppressive treatment in multifocal motor neuropathy. Ann Neurol. 1991 Sep;30(3):397–401. doi: 10.1002/ana.410300312. [DOI] [PubMed] [Google Scholar]
  9. Freddo L., Yu R. K., Latov N., Donofrio P. D., Hays A. P., Greenberg H. S., Albers J. W., Allessi A. G., Keren D. Gangliosides GM1 and GD1b are antigens for IgM M-protein in a patient with motor neuron disease. Neurology. 1986 Apr;36(4):454–458. doi: 10.1212/wnl.36.4.454. [DOI] [PubMed] [Google Scholar]
  10. Kaji R., Shibasaki H., Kimura J. Multifocal demyelinating motor neuropathy: cranial nerve involvement and immunoglobulin therapy. Neurology. 1992 Mar;42(3 Pt 1):506–509. doi: 10.1212/wnl.42.3.506. [DOI] [PubMed] [Google Scholar]
  11. Kermode A. G., Laing B. A., Carroll W. M., Mastaglia F. L. Intravenous immunoglobulin for multifocal motor neuropathy. Lancet. 1992 Oct 10;340(8824):920–921. doi: 10.1016/0140-6736(92)93339-o. [DOI] [PubMed] [Google Scholar]
  12. Leger J. M., Younes-Chennoufi A. B., Chassande B., Davila G., Bouche P., Baumann N., Brunet P. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 1994 Nov;57 (Suppl):46–49. doi: 10.1136/jnnp.57.suppl.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lewis R. A., Sumner A. J., Brown M. J., Asbury A. K. Multifocal demyelinating neuropathy with persistent conduction block. Neurology. 1982 Sep;32(9):958–964. doi: 10.1212/wnl.32.9.958. [DOI] [PubMed] [Google Scholar]
  14. Nobile-Orazio E., Meucci N., Barbieri S., Carpo M., Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993 Mar;43(3 Pt 1):537–544. doi: 10.1212/wnl.43.3_part_1.537. [DOI] [PubMed] [Google Scholar]
  15. Parry G. J., Clarke S. Multifocal acquired demyelinating neuropathy masquerading as motor neuron disease. Muscle Nerve. 1988 Feb;11(2):103–107. doi: 10.1002/mus.880110203. [DOI] [PubMed] [Google Scholar]
  16. Pestronk A., Cornblath D. R., Ilyas A. A., Baba H., Quarles R. H., Griffin J. W., Alderson K., Adams R. N. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol. 1988 Jul;24(1):73–78. doi: 10.1002/ana.410240113. [DOI] [PubMed] [Google Scholar]
  17. Schiff R. I. Transmission of viral infections through intravenous immune globulin. N Engl J Med. 1994 Dec 15;331(24):1649–1650. doi: 10.1056/NEJM199412153312409. [DOI] [PubMed] [Google Scholar]
  18. Shy M. E., Heiman-Patterson T., Parry G. J., Tahmoush A., Evans V. A., Schick P. K. Lower motor neuron disease in a patient with autoantibodies against Gal(beta 1-3)GalNAc in gangliosides GM1 and GD1b: improvement following immunotherapy. Neurology. 1990 May;40(5):842–844. doi: 10.1212/wnl.40.5.842. [DOI] [PubMed] [Google Scholar]
  19. Van den Berg L. H., Kerkhoff H., Oey P. L., Franssen H., Mollee I., Vermeulen M., Jennekens F. G., Wokke J. H. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry. 1995 Sep;59(3):248–252. doi: 10.1136/jnnp.59.3.248. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES